{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:49Z","timestamp":1793146669678,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Italian Ministry of Health - GENERA","award":["CUP E83C22004130005"],"award-info":[{"award-number":["CUP E83C22004130005"]}]},{"name":"Association Fran\u00e7aise de l\u2019Ataxie de Friedreich"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Friedreich ataxia (FRDA) is a life-threatening hereditary ataxia; its incidence is 1:50,000 individuals in the Caucasian population. A unique therapeutic drug for FRDA, the antioxidant Omaveloxolone, has been recently approved by the US Food and Drug Administration (FDA). FRDA is a multi-systemic neurodegenerative disease; in addition to a progressive neurodegeneration, FRDA is characterized by hypertrophic cardiomyopathy, diabetes mellitus and musculoskeletal deformities. Cardiomyopathy is the predominant cause of premature death. The onset of FRDA typically occurs between the ages of 5 and 15. Given the complexity and heterogeneity of clinical features and the variability of their onset, the identification of biomarkers capable of assessing disease progression and monitoring the efficacy of treatments is essential to facilitate decision making in clinical practice. We conducted an RNA-seq analysis in peripheral blood mononuclear cells from FRDA patients and healthy donors, identifying a signature of small non-coding RNAs (sncRNAs) capable of distinguishing healthy individuals from the majority of FRDA patients. Among the differentially expressed sncRNAs, microRNAs are a class of small non-coding endogenous RNAs that regulate posttranscriptional silencing of target genes. In FRDA plasma samples, hsa-miR-148a-3p resulted significantly upregulated. The analysis of the Receiver Operating Characteristic (ROC) curve, combining the circulating expression levels of hsa-miR-148a-3p and hsa-miR-223-3p (previously identified by our group), revealed an Area Under the Curve (AUC) of 0.86 (95%, Confidence Interval 0.77\u20130.95; p-value\u2009&lt;\u20090.0001). An <jats:italic>in silico<\/jats:italic> prediction analysis indicated that the IL6ST gene, an interesting marker of neuroinflammation in FRDA, is a common target gene of both miRNAs. Our findings support the evaluation of combined expression levels of different circulating miRNAs as potent epi-biomarkers in FRDA. Moreover, we found hsa-miR-148a-3p significantly over-expressed in Intermediate and Late-Onset Friedreich Ataxia patients\u2019 group (IOG and LOG, respectively) compared to healthy individuals, indicating it as a putative prognostic biomarker in this pathology.<\/jats:p>","DOI":"10.1186\/s40246-024-00602-y","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:02:03Z","timestamp":1716361323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Chiara","family":"Vancheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Quatrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Morini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fichera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Cond\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Testi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Malisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"602_CR1","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","volume":"6","author":"V Campuzano","year":"1997","unstructured":"Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, et al. Frataxin is reduced in Friedreich Ataxia patients and is Associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771\u201380. https:\/\/doi.org\/10.1093\/hmg\/6.11.1771.","journal-title":"Hum Mol Genet"},{"key":"602_CR2","doi-asserted-by":"publisher","first-page":"NS20180060","DOI":"10.1042\/NS20180060","volume":"2","author":"E Clark","year":"2018","unstructured":"Clark E, Johnson J, Dong YN, Mercado-Ayon E, Warren N, Zhai M, McMillan E, Salovin A, Lin H, Lynch DR. Role of Frataxin Protein Deficiency and metabolic dysfunction in Friedreich Ataxia, an autosomal recessive mitochondrial disease. Neuronal Signal. 2018;2:NS20180060. https:\/\/doi.org\/10.1042\/NS20180060.","journal-title":"Neuronal Signal"},{"key":"602_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen AH. Friedreich\u2019s Ataxia: Pathology, Pathogenesis, and Molecular Genetics. J Neurol Sci. 2011;303:1\u201312. https:\/\/doi.org\/10.1016\/j.jns.2011.01.010.","journal-title":"J Neurol Sci"},{"key":"602_CR4","doi-asserted-by":"publisher","first-page":"16750","DOI":"10.1074\/jbc.M511960200","volume":"281","author":"I Cond\u00f2","year":"2006","unstructured":"Cond\u00f2 I, Ventura N, Malisan F, Tomassini B, Testi R. A Pool of Extramitochondrial Frataxin that promotes cell survival. J Biol Chem. 2006;281:16750\u20136. https:\/\/doi.org\/10.1074\/jbc.M511960200.","journal-title":"J Biol Chem"},{"key":"602_CR5","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1038\/cddis.2011.5","volume":"2","author":"I Guccini","year":"2011","unstructured":"Guccini I, Serio D, Cond\u00f2 I, Rufini A, Tomassini B, Mangiola A, Maira G, Anile C, Fina D, Pallone F, et al. Frataxin participates to the Hypoxia-Induced response in tumors. Cell Death Dis. 2011;2:e123. https:\/\/doi.org\/10.1038\/cddis.2011.5.","journal-title":"Cell Death Dis"},{"key":"602_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.exger.2012.12.002","volume":"48","author":"A Schiavi","year":"2013","unstructured":"Schiavi A, Torgovnick A, Kell A, Megalou E, Castelein N, Guccini I, Marzocchella L, Gelino S, Hansen M, Malisan F, et al. Autophagy induction extends Lifespan and reduces lipid content in response to Frataxin Silencing in C. Elegans. Exp Gerontol. 2013;48:191\u2013201. https:\/\/doi.org\/10.1016\/j.exger.2012.12.002.","journal-title":"Exp Gerontol"},{"key":"602_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/ars.2009.3015","volume":"13","author":"R Santos","year":"2010","unstructured":"Santos R, Lefevre S, Sliwa D, Seguin A, Camadro J-M, Lesuisse E. Friedreich Ataxia: Molecular mechanisms, Redox Considerations, and Therapeutic opportunities. Antioxid Redox Signal. 2010;13:651\u201390. https:\/\/doi.org\/10.1089\/ars.2009.3015.","journal-title":"Antioxid Redox Signal"},{"key":"602_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0022-510x(02)00321-0","volume":"206","author":"J-GG Hou","year":"2003","unstructured":"Hou J-GG, Jankovic J. Movement disorders in Friedreich\u2019s Ataxia. J Neurol Sci. 2003;206:59\u201364. https:\/\/doi.org\/10.1016\/s0022-510x(02)00321-0.","journal-title":"J Neurol Sci"},{"key":"602_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0883073812448535","volume":"27","author":"RM Payne","year":"2012","unstructured":"Payne RM, Wagner GR. Cardiomyopathy in Friedreich Ataxia: clinical findings and research. J Child Neurol. 2012;27:1179\u201386. https:\/\/doi.org\/10.1177\/0883073812448535.","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"602_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jnc.12216","volume":"126","author":"M Cnop","year":"2013","unstructured":"Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich Ataxia. J Neurochem. 2013;126(Suppl 1):94\u2013102. https:\/\/doi.org\/10.1111\/jnc.12216.","journal-title":"J Neurochem"},{"key":"602_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/s1474-4422(14)70321-7","volume":"14","author":"K Reetz","year":"2015","unstructured":"Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, et al. Biological and clinical characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational studies (EFACTS) Cohort: a cross-sectional analysis of Baseline Data. Lancet Neurol. 2015;14:174\u201382. https:\/\/doi.org\/10.1016\/s1474-4422(14)70321-7.","journal-title":"Lancet Neurol"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","volume":"124","author":"A Cook","year":"2017","unstructured":"Cook A, Giunti P. Friedreich\u2019s Ataxia: clinical features, Pathogenesis and management. Br Med Bull. 2017;124:19\u201330. https:\/\/doi.org\/10.1093\/bmb\/ldx034.","journal-title":"Br Med Bull"},{"key":"602_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/jnc.12317","volume":"126","author":"MH Parkinson","year":"2013","unstructured":"Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich\u2019s Ataxia: classical and atypical phenotypes. J Neurochem. 2013;126:103\u201317. https:\/\/doi.org\/10.1111\/jnc.12317.","journal-title":"J Neurochem"},{"key":"602_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe study). Ann Neurol. 2021;89:212\u201325. https:\/\/doi.org\/10.1002\/ana.25934.","journal-title":"Ann Neurol"},{"key":"602_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A, Omaveloxolone. First Approval Drugs. 2023;83:725\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01874-9.","journal-title":"First Approval Drugs"},{"key":"602_CR16","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.celrep.2017.01.079","volume":"18","author":"M Benini","year":"2017","unstructured":"Benini M, Fortuni S, Cond\u00f2 I, Alfedi G, Malisan F, Toschi N, Serio D, Massaro DS, Arcuri G, Testi R, et al. E3 ligase RNF126 directly ubiquitinates Frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich Ataxia. Cell Rep. 2017;18:2007\u201317. https:\/\/doi.org\/10.1016\/j.celrep.2017.01.079.","journal-title":"Cell Rep"},{"key":"602_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mds.27604","volume":"34","author":"G Alfedi","year":"2019","unstructured":"Alfedi G, Luffarelli R, Cond\u00f2 I, Pedini G, Mannucci L, Massaro DS, Benini M, Toschi N, Alaimo G, Panarello L, et al. Drug repositioning screening identifies Etravirine as a potential therapeutic for Friedreich\u2019s Ataxia. Mov Disord. 2019;34:323\u201334. https:\/\/doi.org\/10.1002\/mds.27604.","journal-title":"Mov Disord"},{"key":"602_CR18","doi-asserted-by":"publisher","first-page":"903139","DOI":"10.3389\/fgeed.2022.903139","volume":"4","author":"A Sivakumar","year":"2022","unstructured":"Sivakumar A, Cherqui S. Advantages and limitations of Gene Therapy and Gene Editing for Friedreich\u2019s Ataxia. Front Genome Ed. 2022;4:903139. https:\/\/doi.org\/10.3389\/fgeed.2022.903139.","journal-title":"Front Genome Ed"},{"key":"602_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2022-0011","volume":"12","author":"M Keita","year":"2022","unstructured":"Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Friedreich Ataxia: clinical features and New Developments. Neurodegener Dis Manag. 2022;12:267\u201383. https:\/\/doi.org\/10.2217\/nmt-2022-0011.","journal-title":"Neurodegener Dis Manag"},{"key":"602_CR20","doi-asserted-by":"publisher","unstructured":"Rufini A, Malisan F, Cond\u00f2 I, Testi R. Drug repositioning in Friedreich Ataxia. Front Neurosci. 2022;16. https:\/\/doi.org\/10.3389\/fnins.2022.814445.","DOI":"10.3389\/fnins.2022.814445"},{"key":"602_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/acn3.374","volume":"4","author":"SH Subramony","year":"2016","unstructured":"Subramony SH. Degenerative ataxias: challenges in Clinical Research. Ann Clin Transl Neurol. 2016;4:53\u201360. https:\/\/doi.org\/10.1002\/acn3.374.","journal-title":"Ann Clin Transl Neurol"},{"key":"602_CR22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jacc.2019.07.043","volume":"74","author":"B Rizzacasa","year":"2019","unstructured":"Rizzacasa B, Amati F, Romeo F, Novelli G, Mehta JL. Epigenetic modification in coronary atherosclerosis: JACC Review topic of the Week. J Am Coll Cardiol. 2019;74:1352\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.043.","journal-title":"J Am Coll Cardiol"},{"key":"602_CR23","doi-asserted-by":"publisher","unstructured":"Ma J. The development of epigenetics in the study of Disease Pathogenesis. Adv Exp Med Biol. 2020;1253. https:\/\/doi.org\/10.1007\/978-981-15-3449-2_2.","DOI":"10.1007\/978-981-15-3449-2_2"},{"key":"602_CR24","doi-asserted-by":"publisher","first-page":"e0216363","DOI":"10.1371\/journal.pone.0216363","volume":"14","author":"B Rizzacasa","year":"2019","unstructured":"Rizzacasa B, Morini E, Mango R, Vancheri C, Budassi S, Massaro G, Maletta S, Macrini M, D\u2019Annibale S, Romeo F, et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: a pilot study. PLoS ONE. 2019;14:e0216363. https:\/\/doi.org\/10.1371\/journal.pone.0216363.","journal-title":"PLoS ONE"},{"key":"602_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/ijms24021112","volume":"24","author":"C Vancheri","year":"2023","unstructured":"Vancheri C, Morini E, Prandi FR, Barill\u00e0 F, Romeo F, Novelli G, Amati F. Downregulation of circulating hsa-miR-200c-3p correlates with Dyslipidemia in patients with stable coronary artery disease. Int J Mol Sci. 2023;24:1112. https:\/\/doi.org\/10.3390\/ijms24021112.","journal-title":"Int J Mol Sci"},{"key":"602_CR26","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1111\/jcmm.17492","volume":"26","author":"A Latini","year":"2022","unstructured":"Latini A, Vancheri C, Amati F, Morini E, Grelli S, Matteucci C, Petrone V, Colona VL, Murdocca M, Andreoni M, et al. Expression analysis of miRNA Hsa-Let7b-5p in Naso-Oropharyngeal swabs of COVID-19 patients supports its role in regulating ACE2 and DPP4 receptors. J Cell Mol Med. 2022;26:4940\u20138. https:\/\/doi.org\/10.1111\/jcmm.17492.","journal-title":"J Cell Mol Med"},{"key":"602_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4110\/in.2011.11.3.135","volume":"11","author":"T-Y Ha","year":"2011","unstructured":"Ha T-Y. MicroRNAs in Human diseases: from Cancer to Cardiovascular Disease. Immune Netw. 2011;11:135\u201354. https:\/\/doi.org\/10.4110\/in.2011.11.3.135.","journal-title":"Immune Netw"},{"key":"602_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2217\/bmm-2016-0242","volume":"11","author":"V Viswambharan","year":"2017","unstructured":"Viswambharan V, Thanseem I, Vasu MM, Poovathinal SA, Anitha A. miRNAs as biomarkers of neurodegenerative disorders. Biomark Med. 2017;11:151\u201367. https:\/\/doi.org\/10.2217\/bmm-2016-0242.","journal-title":"Biomark Med"},{"key":"602_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29515","author":"P Schlie\u00dfer","year":"2023","unstructured":"Schlie\u00dfer P, Struebing FL, Northoff BH, Kurz A, R\u00e9mi J, Holdt L, H\u00f6glinger GU, Herms J, Koeglsperger T. Detection of a Parkinson\u2019s Disease-Specific MicroRNA signature in nasal and oral swabs. Mov Disord. 2023. https:\/\/doi.org\/10.1002\/mds.29515.","journal-title":"Mov Disord"},{"key":"602_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-023-03520-7","author":"BC Gomes","year":"2023","unstructured":"Gomes BC, Peixinho N, Pisco R, Gromicho M, Pronto-Laborinho AC, Rueff J, de Carvalho M, Rodrigues AS. Differential expression of miRNAs in amyotrophic lateral sclerosis patients. Mol Neurobiol. 2023. https:\/\/doi.org\/10.1007\/s12035-023-03520-7.","journal-title":"Mol Neurobiol"},{"key":"602_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10565-022-09761-x","volume":"39","author":"S Li","year":"2023","unstructured":"Li S, Lei Z, Sun T. The role of microRNAs in neurodegenerative diseases: a review. Cell Biol Toxicol. 2023;39:53\u201383. https:\/\/doi.org\/10.1007\/s10565-022-09761-x.","journal-title":"Cell Biol Toxicol"},{"key":"602_CR32","doi-asserted-by":"publisher","first-page":"e54791","DOI":"10.1371\/journal.pone.0054791","volume":"8","author":"S Bandiera","year":"2013","unstructured":"Bandiera S, Cartault F, Jannot A-S, Hatem E, Girard M, Rifai L, Loiseau C, Munnich A, Lyonnet S, Henrion-Caude A. Genetic variations creating microRNA Target sites in the FXN 3\u2019-UTR affect Frataxin expression in Friedreich Ataxia. PLoS ONE. 2013;8:e54791. https:\/\/doi.org\/10.1371\/journal.pone.0054791.","journal-title":"PLoS ONE"},{"key":"602_CR33","doi-asserted-by":"publisher","first-page":"9369","DOI":"10.1523\/JNEUROSCI.0059-12.2012","volume":"32","author":"LH Mahishi","year":"2012","unstructured":"Mahishi LH, Hart RP, Lynch DR, Ratan RR. Mir-886-3p levels are elevated in Friedreich Ataxia. J Neurosci. 2012;32:9369\u201373. https:\/\/doi.org\/10.1523\/JNEUROSCI.0059-12.2012.","journal-title":"J Neurosci"},{"key":"602_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.yjmcc.2011.07.001","volume":"51","author":"M Kelly","year":"2011","unstructured":"Kelly M, Bagnall RD, Peverill RE, Donelan L, Corben L, Delatycki MB, Semsarian CA. Polymorphic miR-155 binding site in AGTR1 is Associated with Cardiac Hypertrophy in Friedreich Ataxia. J Mol Cell Cardiol. 2011;51:848\u201354. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.07.001.","journal-title":"J Mol Cell Cardiol"},{"key":"602_CR35","doi-asserted-by":"publisher","unstructured":"Quatrana A, Morini E, Tiano F, Vancheri C, Panarello L, Romano S, Marcotulli C, Casali C, Mariotti C, Mongelli A, et al. Hsa-miR223-3p circulating level is upregulated in Friedreich\u2019s Ataxia and inversely Associated with HCLS1 Associated protein X-1, HAX-1. Hum Mol Genet. 2022;ddac005. https:\/\/doi.org\/10.1093\/hmg\/ddac005.","DOI":"10.1093\/hmg\/ddac005"},{"key":"602_CR36","doi-asserted-by":"publisher","first-page":"180021","DOI":"10.1038\/sdata.2018.21","volume":"5","author":"M Seco-Cervera","year":"2018","unstructured":"Seco-Cervera M, Gonz\u00e1lez-Rodr\u00edguez D, Ib\u00e1\u00f1ez-Cabellos JS, Peir\u00f3-Chova L, Pallard\u00f3 FV, Garc\u00eda-Gim\u00e9nez JL. Small RNA-Seq analysis of circulating miRNAs to identify phenotypic variability in Friedreich\u2019s Ataxia patients. Sci Data. 2018;5:180021. https:\/\/doi.org\/10.1038\/sdata.2018.21.","journal-title":"Sci Data"},{"key":"602_CR37","doi-asserted-by":"publisher","first-page":"104994","DOI":"10.1016\/j.phrs.2020.104994","volume":"159","author":"S Chiang","year":"2020","unstructured":"Chiang S, Huang MLH, Richardson DR. Treatment of dilated cardiomyopathy in a mouse model of Friedreich\u2019s Ataxia using N-Acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis. Pharmacol Res. 2020;159:104994. https:\/\/doi.org\/10.1016\/j.phrs.2020.104994.","journal-title":"Pharmacol Res"},{"key":"602_CR38","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1038\/s41598-017-04996-9","volume":"7","author":"M Seco-Cervera","year":"2017","unstructured":"Seco-Cervera M, Gonz\u00e1lez-Rodr\u00edguez D, Ib\u00e1\u00f1ez-Cabellos JS, Peir\u00f3-Chova L, Gonz\u00e1lez-Cabo P, Garc\u00eda-L\u00f3pez E, V\u00edlchez JJ, Sanz-Gallego I, Pallard\u00f3 FV, Garc\u00eda-Gim\u00e9nez JL. Circulating miR-323-3p Is a biomarker for Cardiomyopathy and an Indicator of phenotypic variability in Friedreich\u2019s Ataxia patients. Sci Rep. 2017;7:5237. https:\/\/doi.org\/10.1038\/s41598-017-04996-9.","journal-title":"Sci Rep"},{"key":"602_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/mds.28825","volume":"37","author":"W Khan","year":"2022","unstructured":"Khan W, Corben LA, Bilal H, Vivash L, Delatycki MB, Egan GF, Harding IH. Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: an [18F]-FEMPA PET study. Mov Disord. 2022;37:218\u201324. https:\/\/doi.org\/10.1002\/mds.28825.","journal-title":"Mov Disord"},{"key":"602_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/hmg\/ddz306","volume":"29","author":"F Tiano","year":"2020","unstructured":"Tiano F, Amati F, Cherubini F, Morini E, Vancheri C, Maletta S, Fortuni S, Serio D, Quatrana A, Luffarelli R, et al. Frataxin Deficiency in Friedreich\u2019s Ataxia is Associated with reduced levels of HAX-1, a Regulator of Cardiomyocyte Death and Survival. Hum Mol Genet. 2020;29:471\u201382. https:\/\/doi.org\/10.1093\/hmg\/ddz306.","journal-title":"Hum Mol Genet"},{"key":"602_CR41","doi-asserted-by":"publisher","first-page":"W460","DOI":"10.1093\/nar\/gkv403","volume":"43","author":"IS Vlachos","year":"2015","unstructured":"Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43:W460\u2013466. https:\/\/doi.org\/10.1093\/nar\/gkv403.","journal-title":"Nucleic Acids Res"},{"key":"602_CR42","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar JN. Receiver operating characteristic curve in Diagnostic Test Assessment. J Thorac Oncol. 2010;5:1315\u20136. https:\/\/doi.org\/10.1097\/JTO.0b013e3181ec173d.","journal-title":"J Thorac Oncol"},{"key":"602_CR43","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s12035-020-01899-1","volume":"57","author":"JO Misiorek","year":"2020","unstructured":"Misiorek JO, Schreiber AM, Urbanek-Trzeciak MO, Jazurek-Ciesio\u0142ka M, Hauser LA, Lynch DR, Napierala JS, Napierala MA. Comprehensive Transcriptome Analysis identifies FXN and BDNF as novel targets of miRNAs in Friedreich\u2019s Ataxia patients. Mol Neurobiol. 2020;57:2639\u201353. https:\/\/doi.org\/10.1007\/s12035-020-01899-1.","journal-title":"Mol Neurobiol"},{"key":"602_CR44","first-page":"6133","volume":"11","author":"S Komatsu","year":"2021","unstructured":"Komatsu S, Imamura T, Kiuchi J, Takashima Y, Kamiya H, Ohashi T, Konishi H, Shiozaki A, Kubota T, Okamoto K, et al. Depletion of tumor suppressor miRNA-148a in plasma relates to Tumor Progression and poor outcomes in gastric Cancer. Am J Cancer Res. 2021;11:6133\u201346.","journal-title":"Am J Cancer Res"},{"key":"602_CR45","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1038\/onc.2016.68","volume":"35","author":"S Bhattacharya","year":"2016","unstructured":"Bhattacharya S, Chalk AM, Ng AJM, Martin TJ, Zannettino AC, Purton LE, Lu J, Baker EK, Walkley CR. Increased mir-155-5p and reduced miR-148a-3p contribute to the suppression of Osteosarcoma Cell Death. Oncogene. 2016;35:5282\u201394. https:\/\/doi.org\/10.1038\/onc.2016.68.","journal-title":"Oncogene"},{"key":"602_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/2211536608666190219095426","volume":"8","author":"JZ Lacerda","year":"2019","unstructured":"Lacerda JZ, Ferreira LC, Lopes BC, Aristiz\u00e1bal-Pach\u00f3n AF, Bajgelman MC, Borin TF, de Zuccari DAP. Therapeutic potential of melatonin in the regulation of miR-148a-3p and angiogenic factors in breast Cancer. Microrna. 2019;8:237\u201347. https:\/\/doi.org\/10.2174\/2211536608666190219095426.","journal-title":"Microrna"},{"key":"602_CR47","doi-asserted-by":"publisher","first-page":"12786","DOI":"10.1002\/jcp.27899","volume":"234","author":"Q Xie","year":"2019","unstructured":"Xie Q, Yu Z, Lu Y, Fan J, Ni Y, Ma L. microRNA-148a-3p inhibited the proliferation and epithelial-mesenchymal transition progression of Non-small-cell Lung Cancer via modulating Ras\/MAPK\/Erk Signaling. J Cell Physiol. 2019;234:12786\u201399. https:\/\/doi.org\/10.1002\/jcp.27899.","journal-title":"J Cell Physiol"},{"key":"602_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/nm.3949","volume":"21","author":"L Goedeke","year":"2015","unstructured":"Goedeke L, Rotllan N, Canfr\u00e1n-Duque A, Aranda JF, Ram\u00edrez CM, Araldi E, Lin C-S, Anderson NN, Wagschal A, de Cabo R, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015;21:1280\u20139. https:\/\/doi.org\/10.1038\/nm.3949.","journal-title":"Nat Med"},{"key":"602_CR49","doi-asserted-by":"publisher","first-page":"143948","DOI":"10.1016\/j.gene.2019.143948","volume":"711","author":"L Shang","year":"2019","unstructured":"Shang L, Quan A, Sun H, Xu Y, Sun G, Cao P. MicroRNA-148a-3p promotes Survival and Migration of endothelial cells isolated from apoe deficient mice through restricting circular RNA 0003575. Gene. 2019;711:143948. https:\/\/doi.org\/10.1016\/j.gene.2019.143948.","journal-title":"Gene"},{"key":"602_CR50","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12033-022-00487-z","volume":"64","author":"W Zhang","year":"2022","unstructured":"Zhang W, Man Y, Chen Z. microRNA-148a in Exosomes derived from bone marrow mesenchymal stem cells alleviates Cardiomyocyte apoptosis in Atrial Fibrillation by inhibiting SMOC2. Mol Biotechnol. 2022;64:1076\u201387. https:\/\/doi.org\/10.1007\/s12033-022-00487-z.","journal-title":"Mol Biotechnol"},{"key":"602_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ymthe.2018.11.011","volume":"27","author":"A Raso","year":"2019","unstructured":"Raso A, Dirkx E, Philippen LE, Fernandez-Celis A, De Majo F, Sampaio-Pinto V, Sansonetti M, Juni R, El Azzouzi H, Calore M, et al. Therapeutic delivery of miR-148a suppresses ventricular dilation in Heart failure. Mol Ther. 2019;27:584\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2018.11.011.","journal-title":"Mol Ther"},{"key":"602_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.omtn.2021.11.019","volume":"27","author":"L Zeng","year":"2022","unstructured":"Zeng L, Jiang H, Ashraf GM, Liu J, Wang L, Zhao K, Liu M, Li Z, Liu R. Implications of miR-148a-3p\/P35\/PTEN signaling in Tau Hyperphosphorylation and autoregulatory feedforward of Akt\/CREB in Alzheimer\u2019s Disease. Mol Ther Nucleic Acids. 2022;27:256\u201375. https:\/\/doi.org\/10.1016\/j.omtn.2021.11.019.","journal-title":"Mol Ther Nucleic Acids"},{"key":"602_CR53","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.3892\/mmr.2019.10152","volume":"19","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Liu H, Cheng J, Zhu Y, Xiao Q, Bai Y, Tao J. Neuroprotective effects of Lithium on a chronic MPTP Mouse Model of Parkinson\u2019s Disease via Regulation of \u0391\u2013synuclein methylation. Mol Med Rep. 2019;19:4989\u201397. https:\/\/doi.org\/10.3892\/mmr.2019.10152.","journal-title":"Mol Med Rep"},{"key":"602_CR54","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41598-020-79543-0","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, Sun M, Li X, Huang L, Gao Z, Gao J, Xie A. MicroRNA expression profiling after recurrent febrile seizures in rat and emerging role of miR-148a-3p\/SYNJ1 Axis. Sci Rep. 2021;11:1262. https:\/\/doi.org\/10.1038\/s41598-020-79543-0.","journal-title":"Sci Rep"},{"key":"602_CR55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/00207454.2014.994209","volume":"126","author":"G Jiang","year":"2016","unstructured":"Jiang G, Zhou R, He X, Shi Z, Huang M, Yu J, Wang X. Expression levels of microRNA-199 and Hypoxia-Inducible Factor-1 alpha in Brain tissue of patients with Intractable Epilepsy. Int J Neurosci. 2016;126:326\u201334. https:\/\/doi.org\/10.3109\/00207454.2014.994209.","journal-title":"Int J Neurosci"},{"key":"602_CR56","doi-asserted-by":"publisher","first-page":"18255","DOI":"10.1073\/pnas.0608791103","volume":"103","author":"E van Rooij","year":"2006","unstructured":"van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke Cardiac Hypertrophy and Heart failure. Proc Natl Acad Sci U S A. 2006;103:18255\u201360. https:\/\/doi.org\/10.1073\/pnas.0608791103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"602_CR57","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/ncb2126","volume":"12","author":"C da Martins","year":"2010","unstructured":"da Martins C, Salic PA, Gladka K, Armand MM, Leptidis A-S, el Azzouzi S, Hansen H, -de Coenen A, Bierhuizen MF, van der Nagel R, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification Loop promoting Calcineurin\/NFAT signalling. Nat Cell Biol. 2010;12:1220\u20137. https:\/\/doi.org\/10.1038\/ncb2126.","journal-title":"Nat Cell Biol"},{"key":"602_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/cvr\/cvw052","volume":"110","author":"Z Li","year":"2016","unstructured":"Li Z, Liu L, Hou N, Song Y, An X, Zhang Y, Yang X, Wang J. Mir-199-Sponge transgenic mice develop physiological Cardiac Hypertrophy. Cardiovasc Res. 2016;110:258\u201367. https:\/\/doi.org\/10.1093\/cvr\/cvw052.","journal-title":"Cardiovasc Res"},{"key":"602_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","volume":"34","author":"C Garbers","year":"2015","unstructured":"Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6\/Gp130\/STAT3 Signaling Axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75\u201382. https:\/\/doi.org\/10.1016\/j.coi.2015.02.008.","journal-title":"Curr Opin Immunol"},{"issue":"e128435","key":"602_CR60","doi-asserted-by":"publisher","first-page":"128435","DOI":"10.1172\/jci.insight.128435","volume":"4","author":"AK Scherger","year":"2019","unstructured":"Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, \u00d6llinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K, et al. Activated Gp130 Signaling selectively targets B Cell differentiation to induce mature lymphoma and Plasmacytoma. JCI Insight. 2019;4(e128435):128435. https:\/\/doi.org\/10.1172\/jci.insight.128435.","journal-title":"JCI Insight"},{"key":"602_CR61","doi-asserted-by":"publisher","first-page":"FFacultyRev1000","DOI":"10.12688\/f1000research.26058.1","volume":"9","author":"S Rose-John","year":"2020","unstructured":"Rose-John S. Interleukin-6 signalling in Health and Disease. F1000Res. 2020;9:FFacultyRev1000\u20131013. https:\/\/doi.org\/10.12688\/f1000research.26058.1.","journal-title":"F1000Res"},{"key":"602_CR62","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbamcr.2016.03.018","volume":"1863","author":"M Rothaug","year":"2016","unstructured":"Rothaug M, Becker-Pauly C, Rose-John S. The role of Interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863:1218\u201327. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.03.018.","journal-title":"Biochim Biophys Acta"},{"key":"602_CR63","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.conb.2013.06.002","volume":"23","author":"M Namihira","year":"2013","unstructured":"Namihira M, Nakashima K. Mechanisms of astrocytogenesis in the mammalian brain. Curr Opin Neurobiol. 2013;23:921\u20137. https:\/\/doi.org\/10.1016\/j.conb.2013.06.002.","journal-title":"Curr Opin Neurobiol"},{"key":"602_CR64","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/hmg\/ddg187","volume":"12","author":"G Tan","year":"2003","unstructured":"Tan G, Napoli E, Taroni F, Cortopassi G. Decreased expression of genes involved in sulfur amino acid metabolism in Frataxin-deficient cells. Hum Mol Genet. 2003;12:1699\u2013711. https:\/\/doi.org\/10.1093\/hmg\/ddg187.","journal-title":"Hum Mol Genet"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-024-00602-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:04:08Z","timestamp":1716361448000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-024-00602-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1186\/s40246-024-00602-y","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Policlinico Tor Vergata-Fondazione PTV (n. 47\/16 and n.56) for studies involving humans. All subjects were enrolled in this study after signing informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this paper consent for publishing the manuscript and figures in the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}